Rescuing Canavan disease: engineering the wrong cell at the right time.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. The full spectrum of MRI findings in 18 patients with Canavan disease: new insights into the areas of selective susceptibility.Neuroradiology · 2024
   Article
2. The pathogenesis of, and pharmacological treatment for, Canavan disease.Drug discovery today · 2022
   Review
3. Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
   Article
4. Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease.Frontiers in molecular neuroscience · 2017
   Article

Corrections and comments

• Comment on
  Redirecting2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as